Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
NCT03136510 · Hopital Lariboisière · NA · terminated · last registry update 2024-07-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “not enough patients” | – | Registry record, Hopital Lariboisière |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F10 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-16Results posted on the registry: Regeneron Pharmaceuticals, REGN9933 + Enoxaparin (NCT05618808)
- 2025-06-22Results posted on the registry: Stanford University, Apixaban 2.5 MG Oral Tablet + Enoxaparin 40Mg/0.4mL Prefilled Syringe (NCT04504318)
- 2025-06-22Also stopped (terminated): Imperial College London, Best medical therapy (NCT05622500)
- 2025-06-18Results posted on the registry: Fadoi Foundation, Italy, Apixaban + Dalteparin (NCT03045406)
- 2025-06-15Also stopped (terminated): Montreal Heart Institute, Rivaroxaban (NCT02387229)
- 2025-06-11Phase 3 first posted: Regeneron Pharmaceuticals, REGN7508 + Apixaban (NCT07015905)
- 2025-06-05Results posted on the registry: Takeda, a drug against F10 (NCT05437211)
- 2025-06-04Phase 3 first posted: University of Vermont, Apixaban 2.5 mg twice daily + Apixaban 5 mg once daily (NCT07005024)
- 2025-05-31Phase 3 first posted: Hoffmann-La Roche, Emicizumab + von Willebrand Factor (VWF) Concentrates (NCT06998524)
- 2025-05-11Phase 3 first posted: Ottawa Hospital Research Institute, Full dose rivaroxaban + Low dose rivaroxaban (NCT06965998)
- 2025-05-08Phase 3 first posted: Kedrion S.p.A., Coagadex(R) (NCT06963216)
- 2025-05-04Results posted on the registry: CytoSorbents, Inc, a drug against F10 (NCT05093504)
- 2025-05-04Also stopped (terminated): CytoSorbents, Inc, a drug against F10 (NCT05093504)
- 2025-04-22Phase 3 first posted: Dhaka Medical College, Emicizumab Injection + Factor VIII (FVIII) (NCT06938659)
- 2025-04-13Phase 3 first posted: Marmara University, Placebo plus immunosuppression + Rivaroxaban plus immunosupression (NCT06925698)
- 2025-04-09Results posted on the registry: Columbia University, Apixaban + Aspirin (NCT03192215)
- 2025-04-09Also stopped (terminated): Columbia University, Apixaban + Aspirin (NCT03192215)
- 2025-03-28Phase 3 first posted: National Taiwan University Hospital, edoxaban + Edoxaban 30 mg (NCT06900725)
- 2025-03-19Also stopped (terminated): University Health Network, Toronto, Rivaroxaban 10 MG + Placebo (NCT05033314)
- 2025-02-25Results posted on the registry: Thomas L. Ortel, Apixaban 2.5 MG + Placebo (NCT04650087)
- 2025-02-06Results posted on the registry: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-02-06Also stopped (terminated): Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-01-17Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Corticosteroids + Rivaroxaban + Corticosteroids alone (NCT06780462)
- 2024-12-27Also stopped (terminated): National Hospital Organization Osaka National Hospital, Oral Anticoagulant + Antiplatelet Drug (NCT03062319)
- 2024-12-19Phase 3 first posted: National Institute of Cardiovascular Diseases, Pakistan, Apixaban 2.5 MG PO BID + Control (Standard treatment) (NCT06742567)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision